1. Home
  2. NX vs XERS Comparison

NX vs XERS Comparison

Compare NX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quanex Building Products Corporation

NX

Quanex Building Products Corporation

HOLD

Current Price

$20.35

Market Cap

939.3M

Sector

Industrials

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.08

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NX
XERS
Founded
1927
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
939.3M
1.0B
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
NX
XERS
Price
$20.35
$6.08
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$28.00
$10.83
AVG Volume (30 Days)
325.3K
1.4M
Earning Date
06-04-2026
05-07-2026
Dividend Yield
1.55%
N/A
EPS Growth
N/A
100.00
EPS
N/A
N/A
Revenue
$1,837,641,000.00
$49,590,000.00
Revenue This Year
$4.26
$34.37
Revenue Next Year
$1.77
$22.86
P/E Ratio
N/A
N/A
Revenue Growth
43.81
142.67
52 Week Low
$11.04
$4.26
52 Week High
$22.90
$10.08

Technical Indicators

Market Signals
Indicator
NX
XERS
Relative Strength Index (RSI) 58.46 52.26
Support Level $18.08 $5.76
Resistance Level $22.64 $6.41
Average True Range (ATR) 0.81 0.22
MACD 0.10 0.01
Stochastic Oscillator 62.94 50.39

Price Performance

Historical Comparison
NX
XERS

About NX Quanex Building Products Corporation

Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: